Obesity-related changes in high-density lipoprotein metabolism

Obesity

Volumn 16, Issue 6, 2008, Pages 1152-1160

  Mooradian, Arshag D ^a   Haas, Michael J ^a   Wehmeier, Kent R ^a   Wong, Norman C W ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

CALORIC INTAKE; EXERCISE; HUMAN; METABOLISM; OBESITY; PHYSIOLOGY; REVIEW;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS; CHOLESTEROL, HDL; ENERGY INTAKE; EXERCISE; HUMANS; LIPOPROTEINS, HDL; OBESITY;

EID: 44449123689     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.202     Document Type: Review

References (103)

1. Willett WC, Manson JE, Stampfer MJ et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995;273:461-465.
2. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North Am men after a 26 year observation period: the Manitoba Study. Am J Cardiol 1977;39:452-458.
3. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977.
4. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-1872.
5. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322:882-889.
6. Dagenais GR, Yi Q, Mann JF et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54-60.
7. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
8. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
9. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
10. López-Candales A. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. J Med 2001;32:283-300.
11. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-1189.
12. Haffner SM, American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(Suppl 1):S68-S71.
13. Hopkins PN, Heiss G, Ellison RC et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003;108:519-523.
14. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006;116:1813-1822.
15. Szapary PO, Rader DJ. The triglyceride-high-density lipoprotein axis: an important target of therapy? Am Heart J 2004;148:211-221.
16. Mooradian AD, Haas MJ, Wong NCW. The effect of select nutrients on serum high density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev 2006;27:2-16.
17. Mooradian AD, Haas MJ, Wong NCW. Transcriptional control of apolipoprotein A-I gene expression in diabetes mellitus. Diabetes 2004;53:513-520.
18. Hachem S, Mooradian AD. Familial dyslipidemias: an overview of pathophysiology and management. Drugs 2006;66:1949-1969.
19. Nissen SE, Tardif J-C, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-1316.
20. Borggreve SE, Hillege HL, Wolffenbuttel BH et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006;91:3382-3388.
21. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-756.
22. Kawahiri M, Maugeais C, Rader D. High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. Curr Atheroscler Rep 2000;2:363-372.
23. Wang M, Briggs MR. HDL: the metabolism, function, and therapeutic importance. Chem Rev 2004;104:119-137.
24. Zheng L, Nukuna B, Brennan ML et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-541.
25. Navab M, Anantharamaiah GM, Reddy ST et al. Mechanisms of disease: proatherogenic HDL - an evolving field. Nat Clin Pract Endocrinol Metab 2006;2:504-511.
26. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359
27. Park YW, Zhu S, Palaniappan L et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-436.
28. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-1214.
29. Meigs JB, Wilson PW, Nathan DM et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003;52:2160-2167.
30. Smith SC. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 2007;120(3 Suppl 1):S3-S11.
31. Brown CD, Higgins M, Donato KA et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000;8:605-619.
32. Mooradian AD, Albert SG, Hass MJ. Low serum HDL cholesterol in obese subjects with normal serum triglycerides: the role of insulin resistance and inflammatory cytokines. Diabetes Obes Metab 2007;9:441-443.
33. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-1069.
34. Vajo Z, Terry JG, Brinton EA. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis 2002;160:495-501.
35. de Vries R, Kerstens MN, Sluiter WJ et al. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005;48:1105-1113.
36. de Vries R, Groen AK, Perton FG et al. Increased cholesterol efflux from cultured fibroblasts to plasma from transfer hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid protein and cholesterol esterification. Atherosclerosis 2008;196:733-741.
37. Dullaart RP, De Vries R, Scheek L et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004;64:205-215.
38. Murao K, Wada Y, Nakamura T et al. Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem 1998;273:18959-18965.
39. Lam JK, Matsubara S, Mihara K et al. Insulin induction of apolipoprotein A, role of Sp1. Biochemistry 2003;42:2680-2690.
40. Haas MJ, Horani M, Mreyoud A et al. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. Biochem Biophys Acta 2003;1623:120-128.
41. Beers A, Haas MJ, Wong NCW, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling. Biochemistry 2006;45:2408-2413.
42. Le NA, Ginsburg HN. Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism 1988;37:614-617.
43. Mooradian AD, Haas MJ, Wong NCW, Chehade JH. Apolipoprotein A-I expression in rats is not altered by troglitazone. Exp Biol Med (Maywood) 2002;227:1001-1005.
44. Sakamoto J, Kimura H, Moriyama S et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-711.
45. Duvillard L, Pont F, Florentin E, Gambert P, Vergès B. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 2000;152:229-237.
46. Mooradian AD, Wong NCW, Shah GN. Apolipoprotein A1 expression in young and aged rats is modulated by dietary carbohydrates. Metabolism 1997;46:1132-1136.
47. Shah NG, Wong NCW, Mooradian AD. Age-related changes in apolipoprotein A-I expression. Biochem Biophys Acta 1995;1259:277-282.
48. Population Studies Data Book Volume 1. The Lipid Research Clinics. NIH publication No. 80-1527, July 1980.
49. Mooradian AD. Obesity: a rational target for managing diabetes mellitus. Growth Horm IGF Res 2001;11(Suppl A):S79-S83.
50. Haas MJ, Horani MH, Wong NCW, Mooradian AD. Induction of the apolipoprotein AI promoter by Sp1 is repressed by saturated fatty acids. Metabolism 2004;53:1342-1348.
51. Mooradian AD, Chehade J, Hurd R, Haas MJ. Monosaccharide-enriched diets cause hyperleptinemia without hypophagia. Nutrition 2000;16:439-441.
52. Mooradian AD, Chehade J. Serum leptin response to endogenous hyperinsulinemia in aging rats. Mech Ageing Dev 2000;115:101-106.
53. Dussault I, Forman BM. Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors. Prostaglandins other Lipid Mediat 2000;62:1-13.
54. Vu-Dac N, Chopin-Delannoy S, Gervois P et al. The nuclear receptors peroxisome proliferator-activated receptor ? and Rev-erb ? mediate the species-specific regulation of apolipoprotein A1 expression by fibrates. J Biol Chem 1998;273:25713-25720.
55. Horani M, Gobal F, Haas MJ, Wong NCW, Mooradian AD. Cyclooxygenase (COX) inhibition is associated with downregulation of apolipoprotein AI promoter activity in cultured hepatoma cell line-HepG2. Metabolism 2004;53:174-181.
56. Weisweiler P. Plasma lipoproteins and lipase and lecithin: cholesterol acyltransferase activities in obese subjects before and after weight reduction. J Clin Endocrinol Metab 1987;65:969-973.
57. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992;56:320-328.
58. James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-2125.
59. Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
60. Ligaray K, Hachem S, Mazza A et al. Repression of apolipoprotein A-I gene expression by anandamide. Diabetes 2007;56(Suppl 1): A56.
61. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-242.
62. Sjöström L, Rissanen A, Andersen T et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-172.
63. Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;35:2683-2693.
64. American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96.
65. Bantle JP, Wylie-Rosett J, Albright AL et al. Nutrition recommendations and interventions for diabetes - 2006: a position statement of the American Diabetes Association. Diabetes Care 2006;29:2140-2157.
66. Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:2265-2272.
67. Berglund L, Oliver EH, Fontanez N et al. HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. Am J Clin Nutr 1999;70:992-1000.
68. Pelkman CL, Fishell VK, Maddox DH et al. Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women. Am J Clin Nutr 2004;79:204-212.
69. Slyper A, Jurva J, Pleuss J, Hoffmann R, Gutterman D. Influence of glycemic load on HDL cholesterol in youth. Am J Clin Nutr 2005;81:376-379.
70. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003;77:1146-1155.
71. Meksawan K, Pendergast DR, Leddy JJ et al. Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women. J Am Coll Nutr 2004;23:131-140.
72. Hatahet W, Cole L, Kudchodkar BJ, Fungwe TV. Dietary fats differentially modulate the expression of lecithin: cholesterol acyltransferase, apoprotein-A1 and scavenger receptor b1 in rats. J Nutr 2003;133:689-694.
73. Sánchez-Muniz FJ, Merinero MC, Rodríguez-Gil S et al. Dietary fat saturation affects apolipoprotein AII levels and HDL composition in postmenopausal women. J Nutr 2002;132:50-54.
74. Walden CE, Retzlaff BM, Buck BL et al. Differential effect of National Cholesterol Education Program (NCEP) Step II diet on HDL cholesterol, its subfractions, and apoprotein A-I levels in hypercholesterolemic women and men after 1 year: the beFIT Study. Arterioscler Thromb Vasc Biol 2000;20:1580-1587.
75. Li Z, Otvos JD, Lamon-Fava S et al. Men and women differ in lipoprotein response to dietary saturated fat and cholesterol restriction. J Nutr 2003;133:3428-3433.
76. Harris WS. n-3 Fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 1996;31:243-252.
77. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006;98:71i-76i.
78. Brousseau ME, Ordovas JM, Osada J et al. Dietary monounsaturated and polyunsaturated fatty acids are comparable in their effects on hepatic apolipoprotein mRNA abundance and liver lipid concentrations when substituted for saturated fatty acids in cynomolgus monkeys. J Nutr 1995;125:425-436.
79. Judd JT, Baer DJ, Clevidence BA et al. Dietary cis and trans monounsaturated and saturated FA and plasma lipids and lipoproteins in men. Lipids 2002;37:123-131.
80. Methane NR, Welty FK, Barrett PH et al. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol 2004;24:1092-1097.
81. Zock PL, Katan MB. Hydrogenation alternatives: effects of trans fatty acids and stearic acid versus linoleic acid on serum lipids and lipoproteins in humans. J Lipid Res 1992;33:399-410.
82. Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med 1990;323:439-445.
83. Reiser S, Powell AS, Scholfield DJ et al. Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch. Am J Clin Nutr 1989;49:832-839.
84. Osei K, Bossetti B. Dietary fructose as a natural sweetener in poorly controlled type 2 diabetes: a 12-month crossover study of effects on glucose, lipoprotein and apolipoprotein metabolism. Diabet Med 1989;6:506-511.
85. Lichtenstein AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res 2006;47:1661-1667
86. Vega-López S, Lichtenstein AH. Dietary protein type and cardiovascular disease risk factors. Prev Cardiol 2005;8:31-40.
87. Potter SM. Overview of proposed mechanism for the hypocholesterolemic effect of soy. J Nutr 1995;125(Suppl 3):S606-S611.
88. Lamon-Fava S, Micherone D. Regulation of apoA-I gene expression: mechanism of action of estrogen and genistein. J Lipid Res 2004;45:106-112.
89. Appel LJ, Sacks FM, Carey VJ et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005;294:2455-2464
90. Cheung MC, Zhao X-Q, Chait A, Albers JJ, Brown G. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001;21:1320-1326.
91. Mooradian AD, Haas MJ, Wadud K. Ascorbic acid and alpha-tocopherol down-regulate apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism 2006;55:159-167.
92. Wehmeier K, Beers A, Haas MJ et al. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta 2005;1737:16-26.
93. Berthou L, Langouet S, Grude P et al. Negative regulation of Apo A-I gene expression by retinoic acid in rat hepatocytes maintained in a coculture system. Biochim Biophys Acta 1998;1391:329-336.
94. Parikh SJ, Edelman M, Uwaifo GI et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004;89:1196-1199.
95. Snijder MB, van Dam RM, Visser M et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab 2005;90:4119-4123.
96. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005;28:1228-1230.
97. Hahn S, Haselhorst U, Tan S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006;114:577-583.
98. Baer DJ, Judd JT, Clevidence BA et al. Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet. Am J Clin Nutr 2002;75:593-599.
99. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lowr risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999;319:1523-1528.
100. Tam SP. Effect of ethanol on lipoprotein secretion in two human hepatoma cell lines, HepG2 and Hep3B. Alcohol Clin Exp Res 1992;16:1021-1028.
101. Williams PT. The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Metabolism 2004;53:700-709
102. Wilund KR, Ferrell RE, Phares DA, Goldberg AP, Hagberg JM. Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype. Metabolism 2002;51:774-778.
103. Halverstadt A, Phares DA, Ferrell RE et al. High-density lipoprotein-cholesterol, its subfractions, and responses to exercise training are dependent on endothelial lipase genotype. Metabolism 2003;52:1505-1511.